StreetInsider.com News Articles

Form 4 UNITED THERAPEUTICS Corp For: Sep 09 Filed by: ROTHBLATT MARTINE A

Thu, 10 Sep 2026 16:31:00 -0400

si-local-file:///var/storage/secattach/20260910/27048883.html

FDA accepts United Therapeutics' drug application for IPF treatment

Wed, 02 Sep 2026 07:05:38 -0400

United Therapeutics Corporation (Nasdaq: UTHR) announced that the U.S. Food and Drug Administration has accepted a supplemental New Drug Application for nebulized Tyvaso (treprostinil) Inhalation Solution to treat idiopathic pulmonary fibrosis (IPF).

The company said it anticipates the FDA's review will be complete in late April 2027. Nebulized Tyvaso has not been approved by the FDA for IPF and remains investigational for this indication.

The application was based on results from the phase 3 TETON-1 and TETON-2 studies. Combined analyses of the two trials met the primary efficacy endpoint, with nebulized Tyvaso showing statistically significant superiority over placebo in the change in

FDA accepts United Therapeutics' drug application for IPF treatment

Wed, 02 Sep 2026 07:05:38 -0400

The company said it anticipates the FDA's review will be complete in late April 2027. Nebulized Tyvaso has not been approved by the FDA for IPF and remains investigational for this indication.

FDA accepts United Therapeutics' sNDA for Tyvaso to treat IPF

Wed, 02 Sep 2026 07:03:38 -0400

United Therapeutics Corporation (NASDAQ: UTHR) announced that the U.S. Food and Drug Administration has accepted a supplemental New Drug Application for nebulized Tyvaso (treprostinil) Inhalation Solution as a treatment for idiopathic pulmonary fibrosis (IPF).

The FDA is expected to complete its review in late April 2027. Nebulized Tyvaso has not been approved for IPF and remains investigational for this indication.

The application was based on results from the phase 3 TETON-1 and TETON-2 clinical studies. Combined analyses of the two trials met the primary efficacy endpoint, with nebulized Tyvaso showing statistically significant superiority over placebo in change in absolute forced vital capacity

FDA accepts United Therapeutics' sNDA for Tyvaso to treat IPF

Wed, 02 Sep 2026 07:03:38 -0400

The FDA is expected to complete its review in late April 2027. Nebulized Tyvaso has not been approved for IPF and remains investigational for this indication.

Form 4 UNITED THERAPEUTICS Corp For: Aug 27 Filed by: ROTHBLATT MARTINE A

Fri, 28 Aug 2026 16:31:00 -0400

si-local-file:///var/storage/secattach/20260828/26998502.html

Form 4 UNITED THERAPEUTICS Corp For: Aug 27 Filed by: ROTHBLATT MARTINE A

Fri, 28 Aug 2026 16:31:00 -0400

si-local-file:///var/storage/secattach/20260828/26998502.html

United Therapeutics presents drug trial data at two European congresses

Fri, 28 Aug 2026 07:00:55 -0400

United Therapeutics Corporation (Nasdaq: UTHR) announced it is presenting eight research abstracts across its drug portfolio at the European Society of Cardiology Congress 2026, held August 28–31 in Munich, and the European Respiratory Society Congress 2026, held September 5–9 in Barcelona, according to a company press release.

The presentations include late-breaking analyses from the phase 3 ADVANCE OUTCOMES study of investigational ralinepag in pulmonary arterial hypertension (PAH), the phase 3 TETON program evaluating nebulized treprostinil in idiopathic pulmonary fibrosis (IPF), and interim data from the ARTISAN study of parenteral treprostinil in PAH.

Data from the ADVANCE OUTCOMES study showed ralinepag achieved clinical

United Therapeutics presents drug trial data at two European congresses

Fri, 28 Aug 2026 07:00:55 -0400

Data from the ADVANCE OUTCOMES study showed ralinepag achieved clinical

United Therapeutics Presents Data at The European Society of Cardiology Congress 2026 and The European Respiratory Society International Congress 2026

Fri, 28 Aug 2026 07:00:00 -0400

ADVANCE OUTCOMES presentations include an analysis showing that ralinepag achieved clinical improvement in a lower risk pulmonary arterial hypertension (PAH) population and reduced clinical worsening in PAH patients with connective tissue disease, in which underlying vascular remodeling and endothelial dysfunction may be accelerated, making PAH more difficult to treat

TETON presentations include analyses showing that nebulized treprostinil improved lung function, demonstrated a consistent benefit in reducing serious clinical worsening events, and showed a dose-dependent magnitude of benefit compared to placebo in idiopathic pulmonary fibrosis (IPF) patients

Additional presentations feature interim data from the ARTISAN study of parenteral treprostinil in PAH patients and

United Therapeutics Presents Data at The European Society of Cardiology Congress 2026 and The European Respiratory Society International Congress 2026

Fri, 28 Aug 2026 07:00:00 -0400

ADVANCE OUTCOMES presentations include an analysis showing that ralinepag achieved clinical improvement in a lower risk pulmonary arterial hypertension (PAH) population and reduced clinical worsening in PAH patients with connective tissue disease, in which underlying vascular remodeling and endothelial dysfunction may be accelerated, making PAH more difficult to treat
TETON presentations include analyses showing that nebulized treprostinil improved lung function, demonstrated a consistent benefit in reducing serious clinical worsening events, and showed a dose-dependent magnitude of benefit compared to placebo in idiopathic pulmonary fibrosis (IPF) patients
Additional presentations feature interim data from the ARTISAN study of parenteral treprostinil in PAH patients and

United Therapeutics Presents Data at The European Society of Cardiology Congress 2026 and The European Respiratory Society International Congress 2026

Fri, 28 Aug 2026 07:00:00 -0400

ADVANCE OUTCOMES presentations include an analysis showing that ralinepag achieved clinical improvement in a lower risk pulmonary arterial hypertension (PAH) population and reduced clinical worsening in PAH patients with connective tissue disease, in which underlying vascular remodeling and endothelial dysfunction may be accelerated, making PAH more difficult to treat
TETON presentations include analyses showing that nebulized treprostinil improved lung function, demonstrated a consistent benefit in reducing serious clinical worsening events, and showed a dose-dependent magnitude of benefit compared to placebo in idiopathic pulmonary fibrosis (IPF) patients
Additional presentations feature interim data from the ARTISAN study of parenteral treprostinil in PAH patients and

United Therapeutics Presents Data at The European Society of Cardiology Congress 2026 and The European Respiratory Society International Congress 2026

Fri, 28 Aug 2026 07:00:00 -0400

ADVANCE OUTCOMES presentations include an analysis showing that ralinepag achieved clinical improvement in a lower risk pulmonary arterial hypertension (PAH) population and reduced clinical worsening in PAH patients with connective tissue disease, in which underlying vascular remodeling and endothelial dysfunction may be accelerated, making PAH more difficult to treat
TETON presentations include analyses showing that nebulized treprostinil improved lung function, demonstrated a consistent benefit in reducing serious clinical worsening events, and showed a dose-dependent magnitude of benefit compared to placebo in idiopathic pulmonary fibrosis (IPF) patients
Additional presentations feature interim data from the ARTISAN study of parenteral treprostinil in PAH patients and

United Therapeutics Presents Data at The European Society of Cardiology Congress 2026 and The European Respiratory Society International Congress 2026

Fri, 28 Aug 2026 07:00:00 -0400

ADVANCE OUTCOMES presentations include an analysis showing that ralinepag achieved clinical improvement in a lower risk pulmonary arterial hypertension (PAH) population and reduced clinical worsening in PAH patients with connective tissue disease, in which underlying vascular remodeling and endothelial dysfunction may be accelerated, making PAH more difficult to treat
TETON presentations include analyses showing that nebulized treprostinil improved lung function, demonstrated a consistent benefit in reducing serious clinical worsening events, and showed a dose-dependent magnitude of benefit compared to placebo in idiopathic pulmonary fibrosis (IPF) patients
Additional presentations feature interim data from the ARTISAN study of parenteral treprostinil in PAH patients and

United Therapeutics Presents Data at The European Society of Cardiology Congress 2026 and The European Respiratory Society International Congress 2026

Fri, 28 Aug 2026 07:00:00 -0400

ADVANCE OUTCOMES presentations include an analysis showing that ralinepag achieved clinical improvement in a lower risk pulmonary arterial hypertension (PAH) population and reduced clinical worsening in PAH patients with connective tissue disease, in which underlying vascular remodeling and endothelial dysfunction may be accelerated, making PAH more difficult to treat
TETON presentations include analyses showing that nebulized treprostinil improved lung function, demonstrated a consistent benefit in reducing serious clinical worsening events, and showed a dose-dependent magnitude of benefit compared to placebo in idiopathic pulmonary fibrosis (IPF) patients
Additional presentations feature interim data from the ARTISAN study of parenteral treprostinil in PAH patients and

United Therapeutics Presents Data at The European Society of Cardiology Congress 2026 and The European Respiratory Society International Congress 2026

Fri, 28 Aug 2026 07:00:00 -0400

ADVANCE OUTCOMES presentations include an analysis showing that ralinepag achieved clinical improvement in a lower risk pulmonary arterial hypertension (PAH) population and reduced clinical worsening in PAH patients with connective tissue disease, in which underlying vascular remodeling and endothelial dysfunction may be accelerated, making PAH more difficult to treat
TETON presentations include analyses showing that nebulized treprostinil improved lung function, demonstrated a consistent benefit in reducing serious clinical worsening events, and showed a dose-dependent magnitude of benefit compared to placebo in idiopathic pulmonary fibrosis (IPF) patients
Additional presentations feature interim data from the ARTISAN study of parenteral treprostinil in PAH patients and

United Therapeutics Presents Data at The European Society of Cardiology Congress 2026 and The European Respiratory Society International Congress 2026

Fri, 28 Aug 2026 07:00:00 -0400

ADVANCE OUTCOMES presentations include an analysis showing that ralinepag achieved clinical improvement in a lower risk pulmonary arterial hypertension (PAH) population and reduced clinical worsening in PAH patients with connective tissue disease, in which underlying vascular remodeling and endothelial dysfunction may be accelerated, making PAH more difficult to treat
TETON presentations include analyses showing that nebulized treprostinil improved lung function, demonstrated a consistent benefit in reducing serious clinical worsening events, and showed a dose-dependent magnitude of benefit compared to placebo in idiopathic pulmonary fibrosis (IPF) patients
Additional presentations feature interim data from the ARTISAN study of parenteral treprostinil in PAH patients and

Form 4 UNITED THERAPEUTICS Corp For: Aug 26 Filed by: ROTHBLATT MARTINE A

Thu, 27 Aug 2026 16:35:00 -0400
si-local-file:///var/storage/secattach/20260827/26990565.html

Form 4 UNITED THERAPEUTICS Corp For: Aug 26 Filed by: ROTHBLATT MARTINE A

Thu, 27 Aug 2026 16:35:00 -0400
si-local-file:///var/storage/secattach/20260827/26990565.html

Form 4 UNITED THERAPEUTICS Corp For: Aug 25 Filed by: ROTHBLATT MARTINE A

Wed, 26 Aug 2026 16:31:00 -0400
si-local-file:///var/storage/secattach/20260826/26982275.html

Form 4 UNITED THERAPEUTICS Corp For: Aug 25 Filed by: ROTHBLATT MARTINE A

Wed, 26 Aug 2026 16:31:00 -0400
si-local-file:///var/storage/secattach/20260826/26982275.html

Form 4 UNITED THERAPEUTICS Corp For: Aug 24 Filed by: ROTHBLATT MARTINE A

Tue, 25 Aug 2026 16:39:00 -0400
si-local-file:///var/storage/secattach/20260825/26975268.html

Form 4 UNITED THERAPEUTICS Corp For: Aug 24 Filed by: ROTHBLATT MARTINE A

Tue, 25 Aug 2026 16:39:00 -0400
si-local-file:///var/storage/secattach/20260825/26975268.html

Form 4 UNITED THERAPEUTICS Corp For: Aug 21 Filed by: ROTHBLATT MARTINE A

Mon, 24 Aug 2026 16:31:00 -0400
si-local-file:///var/storage/secattach/20260824/26968515.html

Form 4 UNITED THERAPEUTICS Corp For: Aug 21 Filed by: ROTHBLATT MARTINE A

Mon, 24 Aug 2026 16:31:00 -0400
si-local-file:///var/storage/secattach/20260824/26968515.html